Key Takeaways TEVA's new drugs Austedo, Ajovy, and Uzedy are driving strong branded sales growth across markets. TEVA plans to double biosimilar sales by 2027, with multiple U.S. and EU launches lined up. Cost cuts, pipeline progress, and debt reduction have lifted investor sentiment.Teva Pharmaceutical Industries Limited’s (TEVA) shares have risen 21.6% in three months.  Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex generics, with many more i ...